These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 7474432)

  • 21. Dysfunctional lipoproteins from young smokers exacerbate cellular senescence and atherogenesis with smaller particle size and severe oxidation and glycation.
    Park KH; Shin DG; Cho KH
    Toxicol Sci; 2014 Jul; 140(1):16-25. PubMed ID: 24798380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo oxidized low density lipoprotein: degree of lipoprotein oxidation does not correlate with its atherogenic properties.
    Tertov VV; Kaplun VV; Orekhov AN
    Mol Cell Biochem; 1998 Jun; 183(1-2):141-6. PubMed ID: 9655188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Atherogenic modification of low-density lipoproteins].
    Sukhorukov VN; Karagodin VP; Orekhov AN
    Biomed Khim; 2016 May; 62(4):391-402. PubMed ID: 27562992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Relation between insulin resistance and small, dense lipoproteins with low density and the development of atherosclerosis in type 2 diabetes mellitus].
    Fábryová L; Cagán S
    Bratisl Lek Listy; 1998; 99(3-4):138-45. PubMed ID: 9919742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipoprotein atherogenicity: an overview of current mechanisms.
    Griffin BA
    Proc Nutr Soc; 1999 Feb; 58(1):163-9. PubMed ID: 10343354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased atherogenicity of low-density lipoprotein in heavy proteinuria.
    Deighan CJ; Caslake MJ; McConnell M; Boulton-Jones JM; Packard CJ
    Nephrol Dial Transplant; 1998 May; 13(5):1183-8. PubMed ID: 9623551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cellular mechanisms of lipid injury in the glomerulus.
    Schlondorff D
    Am J Kidney Dis; 1993 Jul; 22(1):72-82. PubMed ID: 8322798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oxidation of lipoproteins and atherosclerosis.
    Luc G; Fruchart JC
    Am J Clin Nutr; 1991 Jan; 53(1 Suppl):206S-209S. PubMed ID: 1985389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.
    Steinberg D; Parthasarathy S; Carew TE; Khoo JC; Witztum JL
    N Engl J Med; 1989 Apr; 320(14):915-24. PubMed ID: 2648148
    [No Abstract]   [Full Text] [Related]  

  • 30. Oxidative modification of beta-very low density lipoprotein. Potential role in monocyte recruitment and foam cell formation.
    Parthasarathy S; Quinn MT; Schwenke DC; Carew TE; Steinberg D
    Arteriosclerosis; 1989; 9(3):398-404. PubMed ID: 2719599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipoprotein glycation and its metabolic consequences.
    Lyons TJ
    Diabetes; 1992 Oct; 41 Suppl 2():67-73. PubMed ID: 1526339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glycation and oxidation: a role in the pathogenesis of atherosclerosis.
    Lyons TJ
    Am J Cardiol; 1993 Feb; 71(6):26B-31B. PubMed ID: 8434558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Older plasma lipoproteins are more susceptible to oxidation: a linking mechanism for the lipid and oxidation theories of atherosclerotic cardiovascular disease.
    Walzem RL; Watkins S; Frankel EN; Hansen RJ; German JB
    Proc Natl Acad Sci U S A; 1995 Aug; 92(16):7460-4. PubMed ID: 7638213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Particle size: the key to the atherogenic lipoprotein?
    Rajman I; Maxwell S; Cramb R; Kendall M
    QJM; 1994 Dec; 87(12):709-20. PubMed ID: 7859047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diabetes, lipoproteins, and atherosclerosis.
    Schonfeld G
    Metabolism; 1985 Dec; 34(12 Suppl 1):45-50. PubMed ID: 3906360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Modified LDL and atherosclerosis. Nature of modifications. Physicochemical and biological properties].
    Pech MA; Myara I; Vedie B; Moatti N
    Ann Biol Clin (Paris); 1992; 50(4):213-27. PubMed ID: 1456499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyperglycemia, lipoprotein glycation, and vascular disease.
    Veiraiah A
    Angiology; 2005; 56(4):431-8. PubMed ID: 16079928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atherogenecity of lipoprotein(a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux.
    Nielsen LB
    Atherosclerosis; 1999 Apr; 143(2):229-43. PubMed ID: 10217351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [New findings on the pathogenesis of atherosclerosis].
    Fialová L
    Cesk Fysiol; 1995 Jun; 44(2):92-101. PubMed ID: 8665598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determinants of the atherogenic flux of low-density lipoprotein into arteries.
    Born GV; Shafi S; Cusack NJ
    Arzneimittelforschung; 1990 Mar; 40(3A):354-6. PubMed ID: 2185763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.